Nephrolithiasis is the most common type of disease in nephrology, typically manifested by hematuria, proteinuria, edema, hypertension, and can be accompanied by varying degrees of renal hypofunction. Mild nephritis, in the early stages of the disease, has little impact on human life expectancy and can reach an average survival of 76 years after regular drug treatment. For the treatment of nephritis, the focus is on early intervention and early medication. When creatinine and urea are elevated before, there is often a change in urinary routine, an increase in urine protein quantification, which can also manifest as morning eyelid edema and lower limb edema. At this time, you can choose ACEI class or ARB class drugs to reduce urine protein, control blood pressure and treat symptoms. The representative drugs are Irbesartan, Valsartan, Benazepril, etc. The goal of treatment is blood pressure less than 130/80 mmHg and urine protein quantification should be less than 1 g. If the goal is still not achieved by these treatments, renal puncture can be checked to clarify the specific pathological type and choose hormone and immunosuppressive therapy.